Remdesivir Market Outlook 2030

Remdesivir is a broad spectrum anti-viral medication which was firstly developed by Gilead Sciences. It is administered through injection into the vein. Remdesivir is a prodrug of nucleotide. In COVID-19 pandemic remdesivir was authorized for emergency treatment of COVID-19 around the 50 countries as per the recommendation of WHO in November 2020. Originally remdesiver is used in treatment of hepatitis C, Ebola virus, and Marburg virus infections. Moreover, remdesivir can be used in treatment of respiratory infections, feline infections, and arenaviruses. Nausea, liver infection, low blood pressure, and vomiting are common adverse effects of remdesivir.

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the remdesivir market.

Top Impacting Factors

• Rise in cases of viral infections, surge in unhygienic practices in rural areas, increase in demand to overcome from viral infections, surge in cases of COVID-19 across the globe, increase in geriatric population, and rise in hospital acquired infections are the key factors that drive the growth of the remdesivir market.
• In addition, rise in investment in health care sector, occurrence of various pandemic diseases such as Ebola and COVID-19, government initiatives to promote manufacturing of remdesivir, emerging modern healthcare technologies in developing countries, R & D activities to improve quality of remdesivir, launch of novel drugs, and joint ventures, collaboration, and agreements between key market players can boost the growth of the remdesivir market.
• However, shortage of remdesivir supply and availability of substitutes can hinder the growth of the market.
• Contrarily, favourable reimbursement policies by governments and fast track regulatory approvals are expected to offer lucrative opportunities for the expansion of the market.

Market Trends

New Product Launches to Flourish the Market

In 2020, Jubilant Life Sciences announced launch of remdesivir for injection 100mg vial under the brand name JUBI-R. This injection can be used in treatment of COVID-19.

In 2020, Mylan announced commercial launch of remedesivir for injection under the brand name DESREMTM in India. This is a licensed drug for treatment of COVID-19 patients.

In 2020, Zydus Cadila announced launch of remdesivir lyophilised injection 100mg/vial. This injection can be used for patients suffering from SARS-CoV2.

Key Benefits of the Report

• This study presents the analytical depiction of remdesivir market industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the remdesivir market share.
• The current market is quantitatively analyzed to highlight the remdesivir market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Remdesivir Market Report                                   

• Which are the leading players active in the remdesivir market?
• What are the current trends that will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities of the market?
• What future projections would help in taking further strategic steps?
• What is "remdesivir"?
• What is "remdesivir" market prediction in the future?
• Who are the leading global players in the "remdesivir" market?
• What are the current trends and predicted trends?
• What are the key benefits of the "remdesivir" market report?

 Key Market Segments

• By Dosage
  • 2.5MG
  • 5MG
  • 100MG
  • 200MG
• By Form
  • Lyophilized Powder
  • Concentrated Solution
• By Application
  • Ebola
  • SARS-COV
  • MERS-COV
• By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• By Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

 
Key Market Players

• Cipla Ltd.
• Hetero Labs Pvt. Ltd.
• Viatris Pharmaceuticals Ltd. (Mylan Laboratories India Pvt. Ltd.)
• Eva Pharma Pvt. Ltd.
• Sun Pharmaceuticals Industries Ltd.
• Jubilant Life Sciences Ltd.
• Gilead Sciences India Private Limited
• Dr. Reddy’s Laboratories Ltd.
• Zydus Cadila Healthcare Ltd.
• Pfizer Ltd.

• CHAPTER 1: INTRODUCTION

  • 1.1. Report Description

  • 1.2. Key Market Segments

  • 1.3. Key Benefits

  • 1.4. Research Methodology

    • 1.4.1. Primary Research

    • 1.4.2. Secondary Research

    • 1.4.3. Analyst Tools and Models

• CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

• CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope

  • 3.2. Key Findings

    • 3.2.1. Top Investment Pockets

    • 3.2.2. Top Winning Strategies

  • 3.3. Porter's Five Forces Analysis

    • 3.3.1. Bargaining Power of Suppliers

    • 3.3.2. Threat of New Entrants

    • 3.3.3. Threat of Substitutes

    • 3.3.4. Competitive Rivalry

    • 3.3.5. Bargaining Power among Buyers

  • 3.5. Market Dynamics

    • 3.5.1. Drivers

    • 3.5.2. Restraints

    • 3.5.3. Opportunities

• CHAPTER 4: REMDESIVIR MARKET, BY DOSAGE

  • 4.1. Market Overview

    • 4.1.1 Market Size and Forecast, By Dosage

  • 4.2. 2.5MG

    • 4.2.1. Key Market Trends, Growth Factors and Opportunities

    • 4.2.2. Market Size and Forecast, By Region

    • 4.2.3. Market Share Analysis, By Country

  • 4.3. 5MG

    • 4.3.1. Key Market Trends, Growth Factors and Opportunities

    • 4.3.2. Market Size and Forecast, By Region

    • 4.3.3. Market Share Analysis, By Country

  • 4.4. 100MG

    • 4.4.1. Key Market Trends, Growth Factors and Opportunities

    • 4.4.2. Market Size and Forecast, By Region

    • 4.4.3. Market Share Analysis, By Country

  • 4.5. 200MG

    • 4.5.1. Key Market Trends, Growth Factors and Opportunities

    • 4.5.2. Market Size and Forecast, By Region

    • 4.5.3. Market Share Analysis, By Country

• CHAPTER 5: REMDESIVIR MARKET, BY FORM

  • 5.1. Market Overview

    • 5.1.1 Market Size and Forecast, By Form

  • 5.2. Lyophilized Powder

    • 5.2.1. Key Market Trends, Growth Factors and Opportunities

    • 5.2.2. Market Size and Forecast, By Region

    • 5.2.3. Market Share Analysis, By Country

  • 5.3. Concentrated Solution

    • 5.3.1. Key Market Trends, Growth Factors and Opportunities

    • 5.3.2. Market Size and Forecast, By Region

    • 5.3.3. Market Share Analysis, By Country

• CHAPTER 6: REMDESIVIR MARKET, BY APPLICATION

  • 6.1. Market Overview

    • 6.1.1 Market Size and Forecast, By Application

  • 6.2. Ebola

    • 6.2.1. Key Market Trends, Growth Factors and Opportunities

    • 6.2.2. Market Size and Forecast, By Region

    • 6.2.3. Market Share Analysis, By Country

  • 6.3. SARS-COV

    • 6.3.1. Key Market Trends, Growth Factors and Opportunities

    • 6.3.2. Market Size and Forecast, By Region

    • 6.3.3. Market Share Analysis, By Country

  • 6.4. MERS-COV

    • 6.4.1. Key Market Trends, Growth Factors and Opportunities

    • 6.4.2. Market Size and Forecast, By Region

    • 6.4.3. Market Share Analysis, By Country

• CHAPTER 7: REMDESIVIR MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Market Overview

    • 7.1.1 Market Size and Forecast, By Distribution Channel

  • 7.2. Hospital Pharmacy

    • 7.2.1. Key Market Trends, Growth Factors and Opportunities

    • 7.2.2. Market Size and Forecast, By Region

    • 7.2.3. Market Share Analysis, By Country

  • 7.3. Retail Pharmacy

    • 7.3.1. Key Market Trends, Growth Factors and Opportunities

    • 7.3.2. Market Size and Forecast, By Region

    • 7.3.3. Market Share Analysis, By Country

  • 7.4. Online Pharmacy

    • 7.4.1. Key Market Trends, Growth Factors and Opportunities

    • 7.4.2. Market Size and Forecast, By Region

    • 7.4.3. Market Share Analysis, By Country

• CHAPTER 8: REMDESIVIR MARKET, BY REGION

  • 8.1. Market Overview

    • 8.1.1 Market Size and Forecast, By Region

  • 8.2. North America

    • 8.2.1. Key Market Trends and Opportunities

    • 8.2.2. Market Size and Forecast, By Dosage

    • 8.2.3. Market Size and Forecast, By Form

    • 8.2.4. Market Size and Forecast, By Application

    • 8.2.5. Market Size and Forecast, By Distribution Channel

    • 8.2.6. Market Size and Forecast, By Country

    • 8.2.7. U.S. Remdesivir Market

      • 8.2.7.1. Market Size and Forecast, By Dosage

      • 8.2.7.2. Market Size and Forecast, By Form

      • 8.2.7.3. Market Size and Forecast, By Application

      • 8.2.7.4. Market Size and Forecast, By Distribution Channel

    • 8.2.8. Canada Remdesivir Market

      • 8.2.8.1. Market Size and Forecast, By Dosage

      • 8.2.8.2. Market Size and Forecast, By Form

      • 8.2.8.3. Market Size and Forecast, By Application

      • 8.2.8.4. Market Size and Forecast, By Distribution Channel

    • 8.2.9. Mexico Remdesivir Market

      • 8.2.9.1. Market Size and Forecast, By Dosage

      • 8.2.9.2. Market Size and Forecast, By Form

      • 8.2.9.3. Market Size and Forecast, By Application

      • 8.2.9.4. Market Size and Forecast, By Distribution Channel

  • 8.3. Europe

    • 8.3.1. Key Market Trends and Opportunities

    • 8.3.2. Market Size and Forecast, By Dosage

    • 8.3.3. Market Size and Forecast, By Form

    • 8.3.4. Market Size and Forecast, By Application

    • 8.3.5. Market Size and Forecast, By Distribution Channel

    • 8.3.6. Market Size and Forecast, By Country

    • 8.3.7. France Remdesivir Market

      • 8.3.7.1. Market Size and Forecast, By Dosage

      • 8.3.7.2. Market Size and Forecast, By Form

      • 8.3.7.3. Market Size and Forecast, By Application

      • 8.3.7.4. Market Size and Forecast, By Distribution Channel

    • 8.3.8. Germany Remdesivir Market

      • 8.3.8.1. Market Size and Forecast, By Dosage

      • 8.3.8.2. Market Size and Forecast, By Form

      • 8.3.8.3. Market Size and Forecast, By Application

      • 8.3.8.4. Market Size and Forecast, By Distribution Channel

    • 8.3.9. Italy Remdesivir Market

      • 8.3.9.1. Market Size and Forecast, By Dosage

      • 8.3.9.2. Market Size and Forecast, By Form

      • 8.3.9.3. Market Size and Forecast, By Application

      • 8.3.9.4. Market Size and Forecast, By Distribution Channel

    • 8.3.10. Spain Remdesivir Market

      • 8.3.10.1. Market Size and Forecast, By Dosage

      • 8.3.10.2. Market Size and Forecast, By Form

      • 8.3.10.3. Market Size and Forecast, By Application

      • 8.3.10.4. Market Size and Forecast, By Distribution Channel

    • 8.3.11. UK Remdesivir Market

      • 8.3.11.1. Market Size and Forecast, By Dosage

      • 8.3.11.2. Market Size and Forecast, By Form

      • 8.3.11.3. Market Size and Forecast, By Application

      • 8.3.11.4. Market Size and Forecast, By Distribution Channel

    • 8.3.12. Russia Remdesivir Market

      • 8.3.12.1. Market Size and Forecast, By Dosage

      • 8.3.12.2. Market Size and Forecast, By Form

      • 8.3.12.3. Market Size and Forecast, By Application

      • 8.3.12.4. Market Size and Forecast, By Distribution Channel

    • 8.3.13. Rest Of Europe Remdesivir Market

      • 8.3.13.1. Market Size and Forecast, By Dosage

      • 8.3.13.2. Market Size and Forecast, By Form

      • 8.3.13.3. Market Size and Forecast, By Application

      • 8.3.13.4. Market Size and Forecast, By Distribution Channel

  • 8.4. Asia-Pacific

    • 8.4.1. Key Market Trends and Opportunities

    • 8.4.2. Market Size and Forecast, By Dosage

    • 8.4.3. Market Size and Forecast, By Form

    • 8.4.4. Market Size and Forecast, By Application

    • 8.4.5. Market Size and Forecast, By Distribution Channel

    • 8.4.6. Market Size and Forecast, By Country

    • 8.4.7. China Remdesivir Market

      • 8.4.7.1. Market Size and Forecast, By Dosage

      • 8.4.7.2. Market Size and Forecast, By Form

      • 8.4.7.3. Market Size and Forecast, By Application

      • 8.4.7.4. Market Size and Forecast, By Distribution Channel

    • 8.4.8. Japan Remdesivir Market

      • 8.4.8.1. Market Size and Forecast, By Dosage

      • 8.4.8.2. Market Size and Forecast, By Form

      • 8.4.8.3. Market Size and Forecast, By Application

      • 8.4.8.4. Market Size and Forecast, By Distribution Channel

    • 8.4.9. India Remdesivir Market

      • 8.4.9.1. Market Size and Forecast, By Dosage

      • 8.4.9.2. Market Size and Forecast, By Form

      • 8.4.9.3. Market Size and Forecast, By Application

      • 8.4.9.4. Market Size and Forecast, By Distribution Channel

    • 8.4.10. South Korea Remdesivir Market

      • 8.4.10.1. Market Size and Forecast, By Dosage

      • 8.4.10.2. Market Size and Forecast, By Form

      • 8.4.10.3. Market Size and Forecast, By Application

      • 8.4.10.4. Market Size and Forecast, By Distribution Channel

    • 8.4.11. Australia Remdesivir Market

      • 8.4.11.1. Market Size and Forecast, By Dosage

      • 8.4.11.2. Market Size and Forecast, By Form

      • 8.4.11.3. Market Size and Forecast, By Application

      • 8.4.11.4. Market Size and Forecast, By Distribution Channel

    • 8.4.12. Thailand Remdesivir Market

      • 8.4.12.1. Market Size and Forecast, By Dosage

      • 8.4.12.2. Market Size and Forecast, By Form

      • 8.4.12.3. Market Size and Forecast, By Application

      • 8.4.12.4. Market Size and Forecast, By Distribution Channel

    • 8.4.13. Malaysia Remdesivir Market

      • 8.4.13.1. Market Size and Forecast, By Dosage

      • 8.4.13.2. Market Size and Forecast, By Form

      • 8.4.13.3. Market Size and Forecast, By Application

      • 8.4.13.4. Market Size and Forecast, By Distribution Channel

    • 8.4.14. Indonesia Remdesivir Market

      • 8.4.14.1. Market Size and Forecast, By Dosage

      • 8.4.14.2. Market Size and Forecast, By Form

      • 8.4.14.3. Market Size and Forecast, By Application

      • 8.4.14.4. Market Size and Forecast, By Distribution Channel

    • 8.4.15. Rest of Asia Pacific Remdesivir Market

      • 8.4.15.1. Market Size and Forecast, By Dosage

      • 8.4.15.2. Market Size and Forecast, By Form

      • 8.4.15.3. Market Size and Forecast, By Application

      • 8.4.15.4. Market Size and Forecast, By Distribution Channel

  • 8.5. LAMEA

    • 8.5.1. Key Market Trends and Opportunities

    • 8.5.2. Market Size and Forecast, By Dosage

    • 8.5.3. Market Size and Forecast, By Form

    • 8.5.4. Market Size and Forecast, By Application

    • 8.5.5. Market Size and Forecast, By Distribution Channel

    • 8.5.6. Market Size and Forecast, By Country

    • 8.5.7. Brazil Remdesivir Market

      • 8.5.7.1. Market Size and Forecast, By Dosage

      • 8.5.7.2. Market Size and Forecast, By Form

      • 8.5.7.3. Market Size and Forecast, By Application

      • 8.5.7.4. Market Size and Forecast, By Distribution Channel

    • 8.5.8. South Africa Remdesivir Market

      • 8.5.8.1. Market Size and Forecast, By Dosage

      • 8.5.8.2. Market Size and Forecast, By Form

      • 8.5.8.3. Market Size and Forecast, By Application

      • 8.5.8.4. Market Size and Forecast, By Distribution Channel

    • 8.5.9. Saudi Arabia Remdesivir Market

      • 8.5.9.1. Market Size and Forecast, By Dosage

      • 8.5.9.2. Market Size and Forecast, By Form

      • 8.5.9.3. Market Size and Forecast, By Application

      • 8.5.9.4. Market Size and Forecast, By Distribution Channel

    • 8.5.10. UAE Remdesivir Market

      • 8.5.10.1. Market Size and Forecast, By Dosage

      • 8.5.10.2. Market Size and Forecast, By Form

      • 8.5.10.3. Market Size and Forecast, By Application

      • 8.5.10.4. Market Size and Forecast, By Distribution Channel

    • 8.5.11. Argentina Remdesivir Market

      • 8.5.11.1. Market Size and Forecast, By Dosage

      • 8.5.11.2. Market Size and Forecast, By Form

      • 8.5.11.3. Market Size and Forecast, By Application

      • 8.5.11.4. Market Size and Forecast, By Distribution Channel

    • 8.5.12. Rest of LAMEA Remdesivir Market

      • 8.5.12.1. Market Size and Forecast, By Dosage

      • 8.5.12.2. Market Size and Forecast, By Form

      • 8.5.12.3. Market Size and Forecast, By Application

      • 8.5.12.4. Market Size and Forecast, By Distribution Channel

• CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction

  • 9.2. Top Winning Strategies

  • 9.3. Product Mapping Of Top 10 Player

  • 9.4. Competitive Dashboard

  • 9.5. Competitive Heatmap

  • 9.6. Top Player Positioning, 2024

• CHAPTER 10: COMPANY PROFILES

  • 10.1. Cipla Ltd.

    • 10.1.1. Company Overview

    • 10.1.2. Key Executives

    • 10.1.3. Company Snapshot

    • 10.1.4. Operating Business Segments

    • 10.1.5. Product Portfolio

    • 10.1.6. Business Performance

    • 10.1.7. Key Strategic Moves and Developments

  • 10.2. Hetero Labs Pvt. Ltd.

    • 10.2.1. Company Overview

    • 10.2.2. Key Executives

    • 10.2.3. Company Snapshot

    • 10.2.4. Operating Business Segments

    • 10.2.5. Product Portfolio

    • 10.2.6. Business Performance

    • 10.2.7. Key Strategic Moves and Developments

  • 10.3. Jubilant Life Sciences Ltd.

    • 10.3.1. Company Overview

    • 10.3.2. Key Executives

    • 10.3.3. Company Snapshot

    • 10.3.4. Operating Business Segments

    • 10.3.5. Product Portfolio

    • 10.3.6. Business Performance

    • 10.3.7. Key Strategic Moves and Developments

  • 10.4. Viatris Pharmaceuticals Ltd. (Mylan Laboratories India Pvt. Ltd.)

    • 10.4.1. Company Overview

    • 10.4.2. Key Executives

    • 10.4.3. Company Snapshot

    • 10.4.4. Operating Business Segments

    • 10.4.5. Product Portfolio

    • 10.4.6. Business Performance

    • 10.4.7. Key Strategic Moves and Developments

  • 10.5. Dr. Reddy’s Laboratories Ltd.

    • 10.5.1. Company Overview

    • 10.5.2. Key Executives

    • 10.5.3. Company Snapshot

    • 10.5.4. Operating Business Segments

    • 10.5.5. Product Portfolio

    • 10.5.6. Business Performance

    • 10.5.7. Key Strategic Moves and Developments

  • 10.6. Sun Pharmaceuticals Industries Ltd.

    • 10.6.1. Company Overview

    • 10.6.2. Key Executives

    • 10.6.3. Company Snapshot

    • 10.6.4. Operating Business Segments

    • 10.6.5. Product Portfolio

    • 10.6.6. Business Performance

    • 10.6.7. Key Strategic Moves and Developments

  • 10.7. Zydus Cadila Healthcare Ltd.

    • 10.7.1. Company Overview

    • 10.7.2. Key Executives

    • 10.7.3. Company Snapshot

    • 10.7.4. Operating Business Segments

    • 10.7.5. Product Portfolio

    • 10.7.6. Business Performance

    • 10.7.7. Key Strategic Moves and Developments

  • 10.8. Pfizer Ltd.

    • 10.8.1. Company Overview

    • 10.8.2. Key Executives

    • 10.8.3. Company Snapshot

    • 10.8.4. Operating Business Segments

    • 10.8.5. Product Portfolio

    • 10.8.6. Business Performance

    • 10.8.7. Key Strategic Moves and Developments

  • 10.9. Gilead Sciences India Private Limited

    • 10.9.1. Company Overview

    • 10.9.2. Key Executives

    • 10.9.3. Company Snapshot

    • 10.9.4. Operating Business Segments

    • 10.9.5. Product Portfolio

    • 10.9.6. Business Performance

    • 10.9.7. Key Strategic Moves and Developments

  • 10.10. Eva Pharma Pvt. Ltd.

    • 10.10.1. Company Overview

    • 10.10.2. Key Executives

    • 10.10.3. Company Snapshot

    • 10.10.4. Operating Business Segments

    • 10.10.5. Product Portfolio

    • 10.10.6. Business Performance

    • 10.10.7. Key Strategic Moves and Developments

• LIST OF TABLES

• TABLE 1. GLOBAL REMDESIVIR MARKET, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 2. GLOBAL REMDESIVIR MARKET FOR 2.5MG, BY REGION, 2025-2033 ($MILLION)
• TABLE 3. GLOBAL REMDESIVIR MARKET FOR 5MG, BY REGION, 2025-2033 ($MILLION)
• TABLE 4. GLOBAL REMDESIVIR MARKET FOR 100MG, BY REGION, 2025-2033 ($MILLION)
• TABLE 5. GLOBAL REMDESIVIR MARKET FOR 200MG, BY REGION, 2025-2033 ($MILLION)
• TABLE 6. GLOBAL REMDESIVIR MARKET, BY FORM, 2025-2033 ($MILLION)
• TABLE 7. GLOBAL REMDESIVIR MARKET FOR LYOPHILIZED POWDER, BY REGION, 2025-2033 ($MILLION)
• TABLE 8. GLOBAL REMDESIVIR MARKET FOR CONCENTRATED SOLUTION, BY REGION, 2025-2033 ($MILLION)
• TABLE 9. GLOBAL REMDESIVIR MARKET, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 10. GLOBAL REMDESIVIR MARKET FOR EBOLA, BY REGION, 2025-2033 ($MILLION)
• TABLE 11. GLOBAL REMDESIVIR MARKET FOR SARS-COV, BY REGION, 2025-2033 ($MILLION)
• TABLE 12. GLOBAL REMDESIVIR MARKET FOR MERS-COV, BY REGION, 2025-2033 ($MILLION)
• TABLE 13. GLOBAL REMDESIVIR MARKET, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 14. GLOBAL REMDESIVIR MARKET FOR HOSPITAL PHARMACY, BY REGION, 2025-2033 ($MILLION)
• TABLE 15. GLOBAL REMDESIVIR MARKET FOR RETAIL PHARMACY, BY REGION, 2025-2033 ($MILLION)
• TABLE 16. GLOBAL REMDESIVIR MARKET FOR ONLINE PHARMACY, BY REGION, 2025-2033 ($MILLION)
• TABLE 17. GLOBAL REMDESIVIR MARKET, BY REGION, 2025-2033 ($MILLION)
• TABLE 18. NORTH AMERICA REMDESIVIR, BY REGION, 2025-2033 ($MILLION)
• TABLE 19. NORTH AMERICA REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 20. NORTH AMERICA REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 21. NORTH AMERICA REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 22. NORTH AMERICA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 23. U.S. REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 24. U.S. REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 25. U.S. REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 26. U.S. REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 27. CANADA REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 28. CANADA REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 29. CANADA REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 30. CANADA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 31. MEXICO REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 32. MEXICO REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 33. MEXICO REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 34. MEXICO REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 35. EUROPE REMDESIVIR, BY REGION, 2025-2033 ($MILLION)
• TABLE 36. EUROPE REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 37. EUROPE REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 38. EUROPE REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 39. EUROPE REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 40. FRANCE REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 41. FRANCE REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 42. FRANCE REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 43. FRANCE REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 44. GERMANY REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 45. GERMANY REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 46. GERMANY REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 47. GERMANY REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 48. ITALY REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 49. ITALY REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 50. ITALY REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 51. ITALY REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 52. SPAIN REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 53. SPAIN REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 54. SPAIN REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 55. SPAIN REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 56. UK REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 57. UK REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 58. UK REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 59. UK REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 60. RUSSIA REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 61. RUSSIA REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 62. RUSSIA REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 63. RUSSIA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 64. REST OF EUROPE REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 65. REST OF EUROPE REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 66. REST OF EUROPE REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 67. REST OF EUROPE REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 68. ASIA-PACIFIC REMDESIVIR, BY REGION, 2025-2033 ($MILLION)
• TABLE 69. ASIA-PACIFIC REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 70. ASIA-PACIFIC REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 71. ASIA-PACIFIC REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 72. ASIA-PACIFIC REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 73. CHINA REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 74. CHINA REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 75. CHINA REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 76. CHINA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 77. JAPAN REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 78. JAPAN REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 79. JAPAN REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 80. JAPAN REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 81. INDIA REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 82. INDIA REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 83. INDIA REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 84. INDIA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 85. SOUTH KOREA REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 86. SOUTH KOREA REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 87. SOUTH KOREA REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 88. SOUTH KOREA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 89. AUSTRALIA REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 90. AUSTRALIA REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 91. AUSTRALIA REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 92. AUSTRALIA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 93. THAILAND REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 94. THAILAND REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 95. THAILAND REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 96. THAILAND REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 97. MALAYSIA REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 98. MALAYSIA REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 99. MALAYSIA REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 100. MALAYSIA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 101. INDONESIA REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 102. INDONESIA REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 103. INDONESIA REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 104. INDONESIA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 105. REST OF ASIA PACIFIC REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 106. REST OF ASIA PACIFIC REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 107. REST OF ASIA PACIFIC REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 108. REST OF ASIA PACIFIC REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 109. LAMEA REMDESIVIR, BY REGION, 2025-2033 ($MILLION)
• TABLE 110. LAMEA REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 111. LAMEA REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 112. LAMEA REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 113. LAMEA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 114. BRAZIL REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 115. BRAZIL REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 116. BRAZIL REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 117. BRAZIL REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 118. SOUTH AFRICA REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 119. SOUTH AFRICA REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 120. SOUTH AFRICA REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 121. SOUTH AFRICA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 122. SAUDI ARABIA REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 123. SAUDI ARABIA REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 124. SAUDI ARABIA REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 125. SAUDI ARABIA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 126. UAE REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 127. UAE REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 128. UAE REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 129. UAE REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 130. ARGENTINA REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 131. ARGENTINA REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 132. ARGENTINA REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 133. ARGENTINA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 134. REST OF LAMEA REMDESIVIR, BY DOSAGE, 2025-2033 ($MILLION)
• TABLE 135. REST OF LAMEA REMDESIVIR, BY FORM, 2025-2033 ($MILLION)
• TABLE 136. REST OF LAMEA REMDESIVIR, BY APPLICATION, 2025-2033 ($MILLION)
• TABLE 137. REST OF LAMEA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 138. CIPLA LTD.: KEY EXECUTIVES
• TABLE 139. CIPLA LTD.: COMPANY SNAPSHOT
• TABLE 140. CIPLA LTD.: OPERATING SEGMENTS
• TABLE 141. CIPLA LTD.: PRODUCT PORTFOLIO
• TABLE 142. CIPLA LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 143. HETERO LABS PVT. LTD.: KEY EXECUTIVES
• TABLE 144. HETERO LABS PVT. LTD.: COMPANY SNAPSHOT
• TABLE 145. HETERO LABS PVT. LTD.: OPERATING SEGMENTS
• TABLE 146. HETERO LABS PVT. LTD.: PRODUCT PORTFOLIO
• TABLE 147. HETERO LABS PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 148. JUBILANT LIFE SCIENCES LTD.: KEY EXECUTIVES
• TABLE 149. JUBILANT LIFE SCIENCES LTD.: COMPANY SNAPSHOT
• TABLE 150. JUBILANT LIFE SCIENCES LTD.: OPERATING SEGMENTS
• TABLE 151. JUBILANT LIFE SCIENCES LTD.: PRODUCT PORTFOLIO
• TABLE 152. JUBILANT LIFE SCIENCES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 153. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): KEY EXECUTIVES
• TABLE 154. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): COMPANY SNAPSHOT
• TABLE 155. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): OPERATING SEGMENTS
• TABLE 156. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): PRODUCT PORTFOLIO
• TABLE 157. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 158. DR. REDDY’S LABORATORIES LTD.: KEY EXECUTIVES
• TABLE 159. DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
• TABLE 160. DR. REDDY’S LABORATORIES LTD.: OPERATING SEGMENTS
• TABLE 161. DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
• TABLE 162. DR. REDDY’S LABORATORIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 163. SUN PHARMACEUTICALS INDUSTRIES LTD.: KEY EXECUTIVES
• TABLE 164. SUN PHARMACEUTICALS INDUSTRIES LTD.: COMPANY SNAPSHOT
• TABLE 165. SUN PHARMACEUTICALS INDUSTRIES LTD.: OPERATING SEGMENTS
• TABLE 166. SUN PHARMACEUTICALS INDUSTRIES LTD.: PRODUCT PORTFOLIO
• TABLE 167. SUN PHARMACEUTICALS INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 168. ZYDUS CADILA HEALTHCARE LTD.: KEY EXECUTIVES
• TABLE 169. ZYDUS CADILA HEALTHCARE LTD.: COMPANY SNAPSHOT
• TABLE 170. ZYDUS CADILA HEALTHCARE LTD.: OPERATING SEGMENTS
• TABLE 171. ZYDUS CADILA HEALTHCARE LTD.: PRODUCT PORTFOLIO
• TABLE 172. ZYDUS CADILA HEALTHCARE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 173. PFIZER LTD.: KEY EXECUTIVES
• TABLE 174. PFIZER LTD.: COMPANY SNAPSHOT
• TABLE 175. PFIZER LTD.: OPERATING SEGMENTS
• TABLE 176. PFIZER LTD.: PRODUCT PORTFOLIO
• TABLE 177. PFIZER LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 178. GILEAD SCIENCES INDIA PRIVATE LIMITED: KEY EXECUTIVES
• TABLE 179. GILEAD SCIENCES INDIA PRIVATE LIMITED: COMPANY SNAPSHOT
• TABLE 180. GILEAD SCIENCES INDIA PRIVATE LIMITED: OPERATING SEGMENTS
• TABLE 181. GILEAD SCIENCES INDIA PRIVATE LIMITED: PRODUCT PORTFOLIO
• TABLE 182. GILEAD SCIENCES INDIA PRIVATE LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 183. EVA PHARMA PVT. LTD.: KEY EXECUTIVES
• TABLE 184. EVA PHARMA PVT. LTD.: COMPANY SNAPSHOT
• TABLE 185. EVA PHARMA PVT. LTD.: OPERATING SEGMENTS
• TABLE 186. EVA PHARMA PVT. LTD.: PRODUCT PORTFOLIO
• TABLE 187. EVA PHARMA PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS

• LIST OF FIGURES

• FIGURE 1. GLOBAL REMDESIVIR MARKET SEGMENTATION
• FIGURE 2. GLOBAL REMDESIVIR MARKET
• FIGURE 3. SEGMENTATION REMDESIVIR MARKET
• FIGURE 4. TOP INVESTMENT POCKET IN REMDESIVIR MARKET
• FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
• FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
• FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
• FIGURE 8. LOW THREAT OF SUBSTITUTION
• FIGURE 9. HIGH COMPETITIVE RIVALRY
• FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALREMDESIVIR MARKET
• FIGURE 11. REMDESIVIR MARKET SEGMENTATION, BY BY DOSAGE
• FIGURE 12. REMDESIVIR MARKET FOR 2.5MG, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 13. REMDESIVIR MARKET FOR 5MG, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 14. REMDESIVIR MARKET FOR 100MG, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 15. REMDESIVIR MARKET FOR 200MG, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 16. REMDESIVIR MARKET SEGMENTATION, BY BY FORM
• FIGURE 17. REMDESIVIR MARKET FOR LYOPHILIZED POWDER, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 18. REMDESIVIR MARKET FOR CONCENTRATED SOLUTION, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 19. REMDESIVIR MARKET SEGMENTATION, BY BY APPLICATION
• FIGURE 20. REMDESIVIR MARKET FOR EBOLA, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 21. REMDESIVIR MARKET FOR SARS-COV, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 22. REMDESIVIR MARKET FOR MERS-COV, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 23. REMDESIVIR MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
• FIGURE 24. REMDESIVIR MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 25. REMDESIVIR MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 26. REMDESIVIR MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 27. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
• FIGURE 28. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
• FIGURE 29. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
• FIGURE 30. PRODUCT MAPPING OF TOP 10 PLAYERS
• FIGURE 31. COMPETITIVE DASHBOARD
• FIGURE 32. COMPETITIVE HEATMAP: REMDESIVIR MARKET
• FIGURE 33. TOP PLAYER POSITIONING, 2024
• FIGURE 34. CIPLA LTD.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 35. CIPLA LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 36. CIPLA LTD.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 37. HETERO LABS PVT. LTD.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 38. HETERO LABS PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 39. HETERO LABS PVT. LTD.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 40. JUBILANT LIFE SCIENCES LTD.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 41. JUBILANT LIFE SCIENCES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 42. JUBILANT LIFE SCIENCES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 43. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): NET SALES, 2022-2024 ($MILLION)
• FIGURE 44. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 45. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 46. DR. REDDY’S LABORATORIES LTD.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 47. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 48. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 49. SUN PHARMACEUTICALS INDUSTRIES LTD.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 50. SUN PHARMACEUTICALS INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 51. SUN PHARMACEUTICALS INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 52. ZYDUS CADILA HEALTHCARE LTD.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 53. ZYDUS CADILA HEALTHCARE LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 54. ZYDUS CADILA HEALTHCARE LTD.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 55. PFIZER LTD.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 56. PFIZER LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 57. PFIZER LTD.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 58. GILEAD SCIENCES INDIA PRIVATE LIMITED: NET SALES, 2022-2024 ($MILLION)
• FIGURE 59. GILEAD SCIENCES INDIA PRIVATE LIMITED: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 60. GILEAD SCIENCES INDIA PRIVATE LIMITED: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 61. EVA PHARMA PVT. LTD.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 62. EVA PHARMA PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 63. EVA PHARMA PVT. LTD.: REVENUE SHARE, BY REGION, 2024 (%)